Vanguard Global Advisers’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
Other funds holding CLDX
KCM
BBA
Vanguard Global Advisers's CLDX Position: Q3 2026 in Review
Vanguard Global Advisers increased its Celldex Therapeutics (CLDX) stake by 16% in Q3 2026, buying an estimated $175K and bringing the position to 34,020 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1652.
Vanguard Global Advisers first reported a position in CLDX in Q1 2026 and has held it in 3 quarters since. 249 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.
- Vanguard Global Advisers held 34,020 shares of Celldex Therapeutics worth $1.1M as of Q3 2026.
- Vanguard Global Advisers bought 4,567 Celldex Therapeutics shares in Q3 2026, an estimated $175K.
- Celldex Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #1652 holding.
- Vanguard Global Advisers first reported a position in Celldex Therapeutics in Q1 2026 and has held it in 3 quarters since.
- 249 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.